KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) EPS (Basic): 2010-2024

Historic EPS (Basic) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $1.34.

  • Supernus Pharmaceuticals' EPS (Basic) fell 214.29% to -$0.80 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.33, marking a year-over-year decrease of 130.49%. This contributed to the annual value of $1.34 for FY2024, which is 6600.00% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its EPS (Basic) stood at $1.34 for FY2024, which was up 6,600.00% from $0.02 recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' EPS (Basic) peaked at $2.41 during FY2020, and registered a low of $0.02 during FY2023.
  • For the 3-year period, Supernus Pharmaceuticals' EPS (Basic) averaged around $0.83, with its median value being $1.13 (2022).
  • Per our database at Business Quant, Supernus Pharmaceuticals' EPS (Basic) plummeted by 98.23% in 2023 and then surged by 6,600.00% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' EPS (Basic) (Yearly) stood at $2.41 in 2020, then plummeted by 58.09% to $1.01 in 2021, then increased by 11.88% to $1.13 in 2022, then tumbled by 98.23% to $0.02 in 2023, then surged by 6,600.00% to $1.34 in 2024.